Advertisement
"Mammalian cell biotechnology has undergone explosive growth over the last25 years," said Matt Croughan, PhD, the George B. and Joy Rathmann Professorand director of the Amgen Bioprocessing Center at KGI. "There is strong demandfor individuals skilled in mammalian cell biotechnology, and this new programwill allow those in industry the opportunity to become more knowledgeable,operationally adept and business savvy about this growing field."
Advertisement
According to Croughan, recombinant Chinese hamster ovary (CHO) cells nowsurpass E Coli and all other expression systems for recombinant proteinproduction, with total annual sales exceeding $30 billion. Amgen and Genentechmake many of their products, including Enbrel(R) (arthritis), Aranesp(R)(kidney disease, anemia), Herceptin(R) (breast cancer) and Rituxan(R)(non-Hodgkin's lymphoma), from CHO cells.
The primary goal of the course is to provide an advanced background inmammalian cell biotechnology. The scientific, engineering and practicalindustrial aspects will be presented in a series of lectures and laboratoryexercises held in the Amgen Bioprocessing Center at KGI. The lectures willcover a broad range of issues, from cell line engineering and design ofculture medium to control of cell metabolism and operation of high densityfed-batch cultures in large-scale bioreactors. In keeping with KGI's hands-onlearning philosophy, the laboratory exercises will provide experience withmany of the techniques and principles taught in that day's lectures. Courseattendees will gain first-hand experience in setting up, running and analyzingdata from high-density, fed-batch cultures in lab scale Applikon bioreactors.
Croughan was employed at Genentech from 1988 to 1998. In the early 1990s,he led the development of the first FDA-licensed, fed-batch CHO cell cultureprocess, a breakthrough platform technology now used throughout thebiopharmaceutical industry. Over the last 10 years, he has consulted withover 40 firms in biopharmaceutical manufacturing and process development, onproducts ranging from monoclonal antibodies to vaccines, gene therapy vectorsand stem cells.
KGI Background
Educating the future leaders of the bioscience industry, Keck GraduateInstitute (KGI) offers an interdisciplinary graduate education through itsMaster of Bioscience (MBS) degree program and its PhD program in Applied LifeSciences. Using team-based learning and real-world projects, KGI's innovativecurriculum seamlessly combines applied life sciences, bioengineering,bioethics and business management. KGI also has a robust research programconcentrating on the translation of basic discoveries in the life sciencesinto applications that can benefit society. KGI is a member of The ClaremontColleges, located in Claremont, California.
Keck Graduate Institute of Applied Life Sciences is dedicated to educationand research aimed at translating into practice, for the benefit of society,the power and potential of the life sciences.
SOURCE Keck Graduate Institute
